|Day Low/High||51,12 / 52,25|
|52 Wk Low/High||45,17 / 54,26|
AbbVie has been a Sarge fave for a long time. Sarge has been rewarded for trusting this firm's management when they acquired Allergan as a means toward replacing expected reductions in cash flows moving forward as the firm's patents for winder dru...
Life has not been easy for the small-cap biotech investor so far in 2021.
The company behind a diverse roster of shelf and frozen foods sports a big dividend, but that payout may not last because of its large debt.
Among other things, the president works to align Democratic senators to support his massive Covid relief bill.
Plus, Thursday was a solid day for nearly all sectors of the market, though Peloton Interactive pulls back after posting results.
Plus, stay nimble as the road just ahead could become a bit more treacherous than many may think.
A look at the charts of Advanced Micro Devices and Tesla, plus a review of the 'broadening' market action from Thursday.
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.
Often hidden reasons are lurking below when there's maximum confusion, and here's what they are.
Also, interpreting Tuesday's market, Covid-19 vaccine update, and manufacturing growth.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
Markets are clearly different now. I did not grow up, nor was I trained for this environment. Nobody else you hear today was either.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.
I'm long this name, as I am several of the others involved. Will I add on a day like this?
Jerome Powell hit the airwaves with some words of caution and comfort. Nvidia is running into earnings.
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.
More government funding is approved to fight Covid-19 layoffs, Gilead sells off on early reports around China trials and Intel announces earnings.
The drugmaker that is partnering with Sanofi to develop a vaccine has seen its shares push higher after declining to a low in late March.
There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.
The drug and vaccine maker possibly could see its shares double according to a key chart.
Fujifilm Holdings has a promising drug that seems to work in improving the outcome for coronavirus patients in China and Japan, though Avigan is a treatment not a cure.
I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.